We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Method Developed for More Effective Noninvasive Prostate Cancer Screening

By LabMedica International staff writers
Posted on 16 Sep 2014
Print article
Image: Researchers have demonstrated potential for a new, noninvasive method to screen for prostate cancer using a detection system that combines surface-enhanced Raman scattering (SERS) with support vector machine (SVM) techniques (Photo courtesy of Prof. S. Li and Guangdong Medical College).
Image: Researchers have demonstrated potential for a new, noninvasive method to screen for prostate cancer using a detection system that combines surface-enhanced Raman scattering (SERS) with support vector machine (SVM) techniques (Photo courtesy of Prof. S. Li and Guangdong Medical College).
Comparing healthy volunteers and prostate cancer (PrCa) patients, researchers have successfully shown that their new method, which builds on the use of SERS spectroscopy of silver nanoparticles mixed with blood samples, could reveal cases of cancer.

A team of researchers led by Prof. Shaoxin Li, of Guangdong Medical College (Guangdong province, China), has demonstrated potential of a new noninvasive method to screen for PrCa based on combining of the existing technique of serum surface-enhanced Raman scattering (SERS) with the new sophisticated analysis technique called support vector machine (SVM). Applying the combined SERS-SVM system to blood samples collected from 68 healthy volunteers and 93 people clinically confirmed to have PrCa, their technique identified the PrCa cases with 98.1% accuracy.

If the technique proves safe and effective in clinical trials, it may become an effective method available to patients and their doctors for improving early diagnosis of PrCa. “The results demonstrate that label-free serum SERS analysis combined with SVM diagnostic algorithm has great potential,” said Prof. Li, “Compared to traditional screening methods, this method has the advantages of being noninvasive, highly sensitive, and very simple.”

The blood test for elevated levels of PSA (prostate specific antigen) commonly used for PrCa screening and monitoring is far from perfect as elevated PSA levels can be caused by many factors unrelated to cancer. This contributes to over-diagnosis, uncomfortable tissue biopsies, and other unnecessary treatment, which can be costly and carry significant side-effects. Because of this, the US Preventative Services Task Force now recommends against PSA-based screening for PrCa.

Other scientists have considered applying SERS to cancer detection as it would seem to enable detection of the subtle marker signals. The challenge, said Prof. Li, was that the signal differences between the serum samples taken from the healthy volunteers and the PrCa patients were too subtle to detect. So his team employed also the powerful spectral data processing algorithm SVM – and found it to be effective. While the work is preliminary, it demonstrates that the method has good potential for PrCa screening. The next research step, added Prof. Li, is to refine the method and explore whether it can distinguish cancer staging.

The method, described by S. Li et al, was published in the journal Applied Physical Letters, September 2, 2014, online.

Related Links:

Guangdong Medical College


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.